Podcast Episodes
Back to Search
Episode 174: Biotech's trust issues, overwhelmed health workers, & the nuances of insider trading
First, we discuss a sudden spike of FDA rejections, which has resurfaced a time-honored frustration: You can’t always trust biotech companies to be h…
5 years, 2 months ago
Episode 173: Biden's drug pricing plan, Wall Street's Alzheimer's fixation, & daily 5 a.m. alarms
First, STAT Washington correspondent Nicholas Florko joins us to explain President Biden's proposal to lower drug prices, how it might affect the 202…
5 years, 2 months ago
Episode 172: The mRNA gold rush, Delta's alarming rise, & the next treatment for Alzheimer's
First, we dive into the potential of mRNA, a technology that proved itself with Covid-19 vaccines and is now seeding a pharmaceutical gold rush. Then…
5 years, 2 months ago
Episode 171: The quest for a Covid pill, a microbiome gut-check, & CRISPR on the big screen
First, we discuss the CDC's about-face on mask wearing, the debate over vaccine booster shots, and the slow but steady race to develop pills for Covi…
5 years, 3 months ago
Episode 170: Céline Gounder on breakthrough infections, plus the power of lobbying
First, Céline Gounder of NYU’s Grossman School of Medicine joins us to discuss the issue of breakthrough coronavirus infections and whether the U.S. …
5 years, 3 months ago
Episode 169: Dan Diamond on covering Biden, plus the FDA's future, & the latest Aduhelm twist
First, we'll talk about the future of the FDA, whose acting commissioner will have to step down in November unless she’s given the permanent job. Nex…
5 years, 3 months ago
Episode 168: Aduhelm's latest twist, & how Covid variants are shaping the summer
First, we discuss the latest twists following the FDA's widely condemned decision to approve Aduhelm, Biogen's treatment for Alzheimer's disease. The…
5 years, 3 months ago
Episode 167: George Yancopoulos on biotech in 2021, plus a CRISPR milestone, Biogen's FDA saga,
First we talk to George Yancopoulos, head scientist at Regeneron Pharmaceuticals, about the future of CRISPR genome editing and the latest idea for t…
5 years, 4 months ago
Episode 166: FDA inner workings, GSK's foggy future, & the alarming rise in colorectal cancer
First, we sift through the week's news, with a major update from Eli Lilly in Alzheimer's disease and new details on the inner workings of the FDA. T…
5 years, 4 months ago
Episode 165: Paul Offit on the Covid vaccine booster debate, & Robyn Karnauskas' call of the decade
First, we sift through the week's news, with some disappointing Covid-19 vaccine data, a pair of setbacks for biotech, and the Wall Street debut of 2…
5 years, 4 months ago